William Blair initiates Immunome stock coverage with outperform rating

Stifel maintained a Hold rating and $24.00 price target on Immunome (NASDAQ:IMNM) after its licensing deal with Bristol. The stock trades at $21.17, below the analyst consensus. Immunome paid $20M and issued shares to acquire patent rights, simplifying commercialization. The FDA accepted Immunome's NDA for varegacestat, with a target action date of April 28, 2027. H.C. Wainwright reiterated a Buy rating with a $40 target.

Immunome (IMNM) amended its license with Bristol-Myers Squibb, acquiring full patent rights to AL101 and varegacestat for $20M and 4.43M shares. The deal eliminates future milestone and royalty obligations, simplifying the company's economics. Immunome also agreed to register the issued shares for resale by November 16, 2026.

Stifel initiated coverage on Immunome Inc. (IMNM) with a Hold rating and $24 price target, citing uncertainty around its lead drug and pipeline. The stock trades at $21.51, down 10% in a week but up 87% over a year. The FDA accepted Immunome's New Drug Application for varegacestat, with a target action date of April 28, 2027. The company also began a Phase 1 trial for IM-3050. H.C. Wainwright maintains a Buy rating and $40 target.

Immunome Inc. (IMNM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update August 11, 2026 • Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors • Detailed P

Immunome reported $582.7M cash as of March 31 and a Q1 net loss of $53.8M. The article says an insider sale occurred via a preset plan as the FDA accepted Immunome’s varegacestat NDA for review. It cites an FDA decision date of April 28, 2027, based on Phase 3 data showing an 84% lower risk of progression.

Amgen's Imdelltra combined with AstraZeneca's Imfinzi showed a 58% reduction in death risk for extensive-stage small cell lung cancer patients, increasing median survival to 21.1 months. The study, presented at the European Society for Medical Oncology Congress, suggests potential for Imdelltra as a first-line maintenance therapy. Imdelltra reported $288M in Q2 2023 sales and $627M in 2025 global sales.